Haemonetics
296 hedge funds and large institutions have $5.49B invested in Haemonetics in 2021 Q1 according to their latest regulatory filings, with 52 funds opening new positions, 101 increasing their positions, 105 reducing their positions, and 40 closing their positions.
30% more first-time investments, than exits
New positions opened: 52 | Existing positions closed: 40
3% more funds holding
Funds holding: 286 → 296 (+10)
10% more call options, than puts
Call options by funds: $11M | Put options by funds: $10M
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.29% less ownership
Funds ownership: 97.89% → 97.6% (-0.29%)
4% less repeat investments, than reductions
Existing positions increased: 101 | Existing positions reduced: 105
7% less capital invested
Capital invested by funds: $5.89B → $5.49B (-$398M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$105M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
+$71.7M |
| 3 |
Principal Financial Group
Des Moines,
Iowa
|
+$28.1M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$25.8M |
| 5 |
CG
Carmignac Gestion
Paris,
France
|
+$16.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
-$82.3M |
| 2 |
HM
HealthCor Management
New York
|
-$51.7M |
| 3 |
NC
Nitorum Capital
New York
|
-$47.7M |
| 4 |
GKIM
GW&K Investment Management
Boston,
Massachusetts
|
-$36.7M |
| 5 |
Renaissance Technologies
New York
|
-$36.6M |
HAE Hedge Fund Activity: Q1 2021 in Review
296 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Haemonetics (HAE) for Q1 2021, worth a combined $5.49B — down 6.8% from $5.89B a quarter earlier.
Buyers outnumbered sellers: 52 funds opened new HAE positions and 40 closed out — a net gain of 12 holders — while 101 added to existing stakes and 105 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $105M. The largest seller was Wells Fargo, cutting an estimated $82.3M.
- 296 institutional investors held Haemonetics (HAE) as of Q1 2021, up from 286 in Q4 2020.
- Funds reported $5.49B of Haemonetics stock for Q1 2021, down 6.8% quarter-over-quarter.
- 52 funds opened new Haemonetics positions in Q1 2021 and 40 closed out, a net change of +12 holders.
- The largest Haemonetics buyer in Q1 2021 was OrbiMed, an estimated $105M added.
- The largest Haemonetics seller in Q1 2021 was Wells Fargo, an estimated $82.3M sold.
Based on aggregated 13F filings for Q1 2021.